Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Gastroenterology | Nursing | Oncology | Journal

Back to Journal Articles

Common Liver Tests Can Predict Liver Cancer Risk

Last Updated: October 19, 2012.

 

Transaminase levels predict HCC risk in general population; better discrimination than HCV/HBV

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Common liver function tests, including measurement of alanine transaminase and aspartate transaminase levels, can be used to reliably predict hepatocellular carcinoma risk in the general population with average or unknown risk, according to research published in the Oct. 17 issue of the Journal of the National Cancer Institute.

FRIDAY, Oct. 19 (HealthDay News) -- Common liver function tests, including measurement of alanine transaminase (ALT) and aspartate transaminase (AST) levels, can be used to reliably predict hepatocellular carcinoma (HCC) risk in the general population with average or unknown risk, according to research published in the Oct. 17 issue of the Journal of the National Cancer Institute.

Chi-Pang Wen, M.D., M.P.H., Dr.P.H., of the National Health Research Institutes in Zhunan, Taiwan, and colleagues conducted a prospective cohort study involving 130,533 subjects with known hepatitis C virus (HCV) test results and 298,051 subjects without HCV results to examine risk prediction models based on clinically available data.

Over an average of 8.5 years of follow-up, 1,668 incident HCCs occurred. The researchers found that age; sex; health history; HCV and hepatitis B virus (HBV) status; and serum levels of ALT, AST, and alfa-fetoprotein all significantly and independently predicted HCC risk. Discrimination was higher using a model with serum transaminases only, compared with HBV or HCV only (area under the curve [AUC] for transaminases, 0.912; AUC for HBV, 0.840; AUC for HCV, 0.841). Discrimination was improved by adding HBV and HCV data to the transaminase-only model (AUC, 0.933). The high discrimination accuracy and calibration of these models was validated internally.

"This simple tool for the general public more accurately assesses risk even among groups previously thought to be at low or average risk and may be helpful to educate and motivate individuals to pursue options beneficial in reducing their risk of liver cancer and all-cause mortality," the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Intracranial Tumors Can Be Resected Safely in Elderly Next: Report Describes Current State of Interventional Cardiology

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.